Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can PET scans better predict lymphoma outcomes?

NCT ID NCT04333524

Knowledge-focused Sponsor: International Extranodal Lymphoma Study Group (IELSG) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study reviews PET scans from 496 people with marginal zone lymphoma to see how well the scans help with staging and predicting treatment response. Researchers will compare PET results with CT scans and other tests. The goal is to improve how doctors use PET imaging for this type of lymphoma.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors use PET scans more accurately to stage marginal zone lymphoma and predict how patients will respond to treatment.
What could go wrong
This is a retrospective analysis of existing scans, not a new treatment trial. It may not lead to immediate changes in care, and results depend on the quality of previously collected data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

496 people

The number who actually took part.

Started

Dec 2020

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with MZL enrolled in the prospective IELSG36 and IELSG38 trials and on the observational NF10, with the possibility to add additional cases from participating institutions

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. One of the following subtypes of Histology confirmed Indolent non-follicular B-cell lymphoma: * Splenic MZL (bone marrow histology and/or splenic tissue); * Extranodal MZL or MALT (tissue biopsy); * Nodal MZL (lymph node biopsy). 2. Age over 18. 3. Availability of details on clinical presentation, treatment details and results, and on follow-up. 4. Execution of PET at diagnosis or/and at end of treatment or/and at relapse. 5. Execution of CT scan with iodine contrast medium at diagnosis and at assessment of response. 6. Patients with histologically confirmed marginal zone lymphomas according to the current WHO classification are registered in the study. Diagnosis based on tru-cut core-needle biopsies are permitted in the study. 7. Written informed consent. Exclusion Criteria: 1. Patients with a diagnosis of Non Hodgkin Lymphoma other than MZL. 2. Scans images not available for whatever reason. 3. Cases diagnosed on fine needle aspiration cytology only.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Marginal zone lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Marginal zone lymphoma

Contacts and locations

Locations

  • "G. Rodolico", AOU Policlinico Vittorio Emanuele

    Catania, CT, 95123, Italy

  • A.O. Santa Maria di Terni

    Terni, TR, 05100, Italy

  • A.O.U. Città della Salute e della Scienza di Torino

    Torino, TO, 10126, Italy

  • AOU Federico II

    Naples, 80131, Italy

  • AOU Policlinico "Paolo Giaccone"

    Palermo, PA, 90144, Italy

  • ASO SS. Antonio e Biagio e C. Arrigo

    Alessandria, AL, 15121, Italy

  • AUSL IRCCS Reggio Emilia

    Reggio Emilia, 42123, Italy

  • Azienda Ospedaliera - Ospedale di Circolo e Fondazione Macchi di Varese

    Varese, VA, 21100, Italy

  • CHU de Dijon

    Dijon, 21000, France

  • Fondazione IRCCS - Cà Granda Ospedale Maggiore Policlinico

    Milan, MI, 20122, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, MI, 20133, Italy

  • Fondazione IRCCS Policlinico S. Matteo di Pavia

    Pavia, PV, 27100, Italy

  • Hôpiteux Universitaires de Genève (HUG)

    Geneva, Canton of Geneva, 1205, Switzerland

  • I.R.C.C.S. Istituto Oncologico Veneto

    Padova, PD, 35128, Italy

  • IRCCS Centro di Riferimento Oncologico di Aviano

    Aviano, PN, 33081, Italy

  • IRCCS Istituto Tumori "Giovanni Paolo II"

    Bari, 70124, Italy

  • IUCT Oncopole Toulouse

    Toulouse, 31100, France

  • Istituto Oncologico della Svizzera Italiana

    Bellinzona, Canton Ticino, 6500, Switzerland

  • Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS

    Candiolo, TO, 10060, Italy

  • Ospedale Civile Spirito Santo Pescara

    Pescara, PE, 65124, Italy

  • Ospedale Oncologico Businco

    Cagliari, CA, 09121, Italy

  • Ospedale San Raffaele

    Milan, MI, 20132, Italy

  • Ospedale degli Infermi

    Ponderano, BI, 13875, Italy

  • Policlinico GB Rossi

    Verona, VR, 37134, Italy

  • Saint Louis Hospital

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.